Mednax Can Susstain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
In a report released this morning, Morgan Keegan said that it believes that Mednax, Inc. (NYSE: MD) can sustain EPS growth by consolidating neonatology, anesthesiology, and related group medical practices.
“We believe the company's entry into the anesthesiology sector will enable it to continue to grow through accretive all-cash acquisitions of medical groups,” Morgan Keegan writes. “Our Market Perform rating is due to continued soft neonatology intensive care unit volumes and our concern that an increased proportion of lower-paying government-reimbursed admissions could occur.”
Morgan Keegan said that its EPS estimate of $1.05 versus $1.03 in the prior year period is in line with the First Call consensus, adding, “We are confident that the company's earnings will at least meet Mednax's guidance of $1.03-$1.07.”
Mednax closed Friday at $56.96.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.